Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LESSINA-21 vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Suppresses gonadotropin release (FSH, LH) from pituitary, inhibiting ovulation. Causes cervical mucus thickening and endometrial alterations, impeding sperm penetration and implantation.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Prevention of pregnancy (FDA-approved)
Prevention of pregnancy
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days placebo or no tablets.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
17-21 hours (terminal elimination half-life; clinical significance: allows once-daily dosing, but missed doses increase risk of ovulation)
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Ethinyl estradiol: primarily metabolized by CYP3A4, undergoes first-pass metabolism in gut wall and liver. Levonorgestrel: metabolized via reduction and conjugation, partially involving CYP3A4.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Renal (70% as unchanged drug and metabolites), fecal (30% as metabolites)
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
98-99% (albumin and sex hormone-binding globulin, SHBG)
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
2-4 L/kg (extensive distribution into tissues, reflecting lipophilicity and binding to steroid receptors)
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral: 88% (high bioavailability due to extensive absorption and minimal first-pass metabolism)
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe impairment; use with caution.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Contraindicated in acute hepatitis, severe decompensated cirrhosis (Child-Pugh C), or liver tumors. For mild (Child-Pugh A) to moderate (Child-Pugh B) impairment, use only if benefits outweigh risks; monitor liver function.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Use only after menarche. Same dosing as adults (0.1 mg/0.02 mg daily for 21 days) for adolescents aged 12-17 years. Safety and efficacy not established in premenarchal girls.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
Not indicated for postmenopausal women. No specific geriatric dosing; consider increased risk of thromboembolic events and cardiovascular disease in women over 35 who smoke.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who smoke and use OCs should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Thrombotic disorders (venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction) - discontinue if signs occur,Increased risk of myocardial infarction and stroke, especially in smokers >35 years,Hepatic neoplasia (benign/malignant) - discontinue if jaundice or hepatic adenoma develops,Hypertension - monitor blood pressure; discontinue if hypertension develops,Gallbladder disease,Carbohydrate/lipid metabolism effects,Headache - evaluate if new/worsening migraine,Bleeding irregularities (breakthrough bleeding, amenorrhea),Ocular lesions (retinal thrombosis) - discontinue if unexplained vision loss,Depression - discontinue if severe,Reduce efficacy with certain drugs (e.g., anticonvulsants, antibiotics)
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Known or suspected pregnancy,Current or past history of thromboembolic disorders (e.g., DVT, PE),Cerebrovascular or coronary artery disease (current or history),Known thrombophilic conditions (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Uncontrolled hypertension (BP ≥160/100 mm Hg),Diabetes with vascular involvement,Headaches with focal neurological symptoms (e.g., migraine with aura, age >35),Major surgery with prolonged immobilization,Known or suspected breast carcinoma or other estrogen-sensitive neoplasia,Hepatic adenoma or carcinoma, active liver disease, or impaired liver function,Undiagnosed abnormal uterine bleeding,Cigarette smoking in women >35 years,Hypersensitivity to any component
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
Avoid grapefruit and grapefruit juice as they may increase ethinyl estradiol levels. No other significant food interactions. St. John's wort (herbal supplement) reduces contraceptive efficacy.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
FDA Pregnancy Category X. First trimester: oral contraceptive use is associated with a slight increase in cardiovascular defects and limb reduction defects, though absolute risk is low. Second and third trimesters: no increased risk of major malformations; however, exposure may increase risk of neonatal jaundice, cholestasis, and transient hormonal effects. Discontinue if pregnancy is suspected.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Small amounts of ethinyl estradiol and levonorgestrel are excreted in breast milk (M/P ratio not determined). May reduce milk production and composition. Use is generally not recommended during breastfeeding; alternative contraception should be considered.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
Contraindicated in pregnancy; no dose adjustments are applicable. Discontinue use immediately if pregnancy is confirmed.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
Lessina-21 is a low-dose combination oral contraceptive containing 0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol. Administer on day 1 of menstrual period or first Sunday after onset. Use backup contraception for first 7 days if starting after day 5. Missed pill management: if one pill missed, take as soon as remembered; if two pills missed, take two pills on two consecutive days. CYP34A inducers (e.g., rifampin, St. John's wort) reduce efficacy; consider alternative contraception. Monitor for hypertension, thromboembolism, and migraine with aura. Eating grapefruit may increase ethinyl estradiol levels. Avoid in patients with migraine with aura, history of VTE, or breast cancer.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take one pill at the same time every day. Do not skip pills.,Start your pack on the first day of your period or the first Sunday after your period starts.,If you miss one pill, take it as soon as you remember. If you miss two pills, take two pills for two days and use a backup method for 7 days.,Lessina-21 does not protect against STIs; use condoms.,Common side effects include nausea, headache, and breast tenderness; these often improve after 3 months.,Smoking increases risk of serious cardiovascular side effects; avoid smoking, especially if over 35 years old.,Call your doctor if you have leg pain, chest pain, shortness of breath, or severe headaches.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LESSINA-21 vs ALYACEN 7/7/7, answered by our medical review team.
LESSINA-21 is a Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Suppresses gonadotropin release (FSH, LH) from pituitary, inhibiting ovulation. Causes cervical mucus thickening and endometrial alterations, impeding sperm penetration and implantation.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LESSINA-21 and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LESSINA-21 is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days placebo or no tablets.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LESSINA-21 and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LESSINA-21 is classified as Category C. FDA Pregnancy Category X. First trimester: oral contraceptive use is associated with a slight increase in cardiovascular defects and limb reduction defects, though absolute risk is. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.